Sonar and AWS Expand Collaboration to Drive Adoption of Clean Code Practices
Sonar, the leader in Clean Code solutions, today announced the expansion of its collaboration with Amazon Web Services (AWS) to help enterprises achieve high-quality code that is clean. SonarCloud, Sonar’s SaaS offering, will be available as an integration with Amazon CodeCatalyst, a unified software development service. Additionally, SonarCloud is now certified by the AWS Foundational Technical Review (FTR) – a set of guidelines to reduce risks around security, reliability, and operational excellence, as defined by the AWS Well-Architected Framework.
“With SonarCloud we enabled our engineering teams to drive consistent code quality and standards across the whole organization. The easy integration into our development toolchain and the simple UI allow us to scale fast and without any issues. The wide adoption and the excellent customer support help you overcome any difficulties,” said Andre Ostermeier, Lead Solutions Architect at Relayr. “Besides that, SonarCloud is an excellent tool to drive Engineering KPIs and should not be underestimated by IT leaders.”
SonarCloud and Amazon CodeCatalyst: Improving Development Processes
Amazon CodeCatalyst features blueprint capabilities that allow customers to automatically set up everything they need to start a new software development project, including continuous integration and delivery (CI/CD) pipelines, deployable code, issue tracking, and fully configured AWS services.
“Customers building apps need to release code early and often, and with solid DevOps practices and tools,” said Nicolas Pujol, ISV Partner Management Leader in EMEA, AWS. “Sonar has done a great job giving developers and DevOps leaders solutions to be more productive, and we’re excited to collaborate to make these tools available to AWS customers.”
Amazon CodeCatalyst paired with Sonar’s unique Clean as You Code approach, delivered through SonarCloud, empowers developers to spend more time writing innovative code and less time managing local development environments. With SonarCloud integrated into Amazon CodeCatalyst CI/CD workflows, development teams can more easily ensure that only clean code will be added to their code base, improving the overall quality of the code written.
Sonar Puts Customer Experience First
Sonar achieved the AWS Foundational Technical Review (FTR) certification by demonstrating that SonarCloud meets best practices critical for a customer’s success. SonarCloud allows for shared expectations across teams rooted in clean code practices, automates code quality checks, and provides extensive feedback for issue resolution.
Sonar’s Clean as You Code Approach
The Clean as You Code approach enables developers and organizations to improve development velocity, code quality, and code security. This simple yet powerful methodology progressively improves the overall quality of the entire codebase as the code is written, with minimal cost and effort. Clean as You Code puts developers in the driver's seat where they take full ownership of the quality of the code they write.
“An increasing number of developers are writing code and building apps in the cloud. We created SonarCloud to provide these developers an easy way to achieve a state of Clean Code, designing a tool that seamlessly integrates with DevOps platforms,” said Fabrice Bellingard, VP of Products at Sonar. “Our growing collaboration with AWS will help more cloud-based development teams create high-quality code with our unique Clean as You Code methodology.”
Today, SonarCloud has over 100,000 active users. The solution has helped a wide range of organizations clean over 2.5 billion lines of code. SonarCloud is free to use on open-source projects. To learn more about SonarCloud, visit here.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610167595/en/
Contact information
Media
Katie Hyman
Senior PR Manager, Sonar
katie.hyman@sonarsource.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom